Yes, targeting catalytic processes in tumor metabolism is a promising strategy for cancer therapy. Inhibitors that specifically target enzymes involved in key metabolic pathways can disrupt the metabolic homeostasis of cancer cells, leading to cell death. For example, inhibitors of isocitrate dehydrogenase (IDH) have shown efficacy in treating certain types of cancers by blocking the production of the oncometabolite 2-hydroxyglutarate. Similarly, targeting glutaminase, an enzyme that catalyzes the conversion of glutamine to glutamate, can deprive cancer cells of essential nutrients.
